Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$431.3MCash on Hand
16.1mo Cash Runway
Follow ALMS by emailGet an email when ALMS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ALMS, unsubscribe in one click. Privacy
📣 What ALMS Says Is Next
in 2027 · A-005: “Alumis plans to initiate a Phase 2 biomarker trial for A-005, its central nervous system (CNS) penetrant TYK2 inhibitor, in patients with Parkinson’s disease, in 2027.”
Company press release, Nov 12, 2026 · SEC filing
fourth quarter of 2026 · Envudeucitinib: “Alumis remains on track to submit its New Drug Application to the FDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026. Envudeucitinib: Systemic Lupus Erythematosus (SLE)”
Company press release, Nov 12, 2026 · SEC filing
fourth quarter of 2026 · “Alumis has reported positive results from its Phase 3 ONWARD program of envudeucitinib in moderate-to-severe plaque psoriasis and plans to file an NDA in moderate-to-severe plaque psoriasis in the fourth quarter of 2026.”
Company press release, Sep 1, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Clinical trial Reported Q3 2026 net loss of $94.9 million, with cash of $431.3 million. Phase 2 LUMUS trial of envudeucitinib in lupus missed its primary and secondary endpoints overall. NDA for psoriasis remains on track for Q4 2026. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Sep 1, 2026 ·
Clinical trial Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus missed its primary and secondary endpoints in the overall population. The prespecified IFNGS-high subgroup showed robust responses, and the company plans to engage regulators on Phase 3 development. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Earnings Reported Q2 2026 net loss of $142.2 million, including a $41.8 million impairment on the lonigutamab program; cash and securities were $502.3 million, funding operations into Q4 2027. ONWARD3 long-term data showed 54% of patients reached PASI 100 at 48 weeks, with NDA submission for envudeucitinib planned for Q4 2026. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 10, 2026 ·
Clinical trial Alumis reported ONWARD3 long-term data for envudeucitinib in plaque psoriasis: 54% of patients reached PASI 100 and 75% reached PASI 90 after 48 weeks of continuous treatment, with a safety profile consistent with prior data. The company plans to submit a New Drug Application to the FDA in 4Q 2026. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2027 · Phase 2 · Active Trial · Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis Registry primary completion date, not a results date
Nov 2028 · Phase 3 · Active Trial · Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis Registry primary completion date, not a results date
Jun 2026 · Phase 2 · Active Trial · Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus Registry date passed, readout not confirmed
Also used in these trials (approved or third-party drugs, not ALMS's own candidates): Apremilast.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ALMS holds $431.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $80.5M/quarter from operations,
an estimated runway of 16.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:43 · Elevated
Cash runway 16 months +18
Shelf registration (S-3, Jul 2025) +10
Going-concern doubt in the latest 10-Q +15The Company believes that, based on its current operating plan, its existing cash, cash equivalents and marketable securities of $ 431.3 million as of September 30, 2026, will not be sufficient to meet its operating and capital requirements for at least 12 months from the date of issuance of these unaudited condensed…10-Q, Nov 2026
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALMS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.